AI Is Making Drug Pipelines Bigger. It Might Also Be Making Them Worse.

AI is expanding drug candidate pipelines by accelerating molecular design, but this increases failure rates as the fundamental clinical challenges in patient targeting and mechanism validation remain unaddressed. Experts argue that AI investment should shift from speeding chemistry to understanding causal human biology and predictive patient response models to improve clinical success.

This Wire brief sits within Fusion42's coverage of Drug Discovery, AI Frontier Models and Biotech.